Imagery Rescripting for treating depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of Imagery Rescripting (ImRs) as a treatment for Major Depressive Disorder (MDD) and Persistent Depressive Disorder (PDD). Participants will undergo a wait period of 6-10 weeks, followed by a preparation phase and then 12 weekly sessions of ImRs. The study will assess changes in depression severity and dysfunctional beliefs using validated questionnaires and visual analogue scales. Follow-up assessments will occur at 5 weeks, 6 months, and 12 months post-treatment to evaluate the long-term effects of the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Primary diagnosis of MDD as assessed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (SCID-5)
* Total score of 20\* or above on the BDI-II (cut-off score for moderate depression) (Beck et al., 1996). (\*Based on previous research by Brewin et al. (2009) \& Yuen-tin (2017) demonstrating averages of BDI-II: 34-35, in their population.)
* Age 18-65
* Dutch or English as a first language (or estimated as sufficient to receive treatment in either of these languages without interpreter)
* Willingness to participate in the study (signed informed consent)

Exclusion Criteria:

* DSM-5 Bipolar disorder, type 1 (current or past); if there has been no manic episode the last year patients will be included
* Psychotic disorders (though psychotic features alongside depression will be allowed)
* Organic brain disease
* Intelligence Quotient (IQ) \< 80
* High risk of self-harm or suicide
* Current substance abuse severe level
* Start of new medication within 2 months before beginning the study (medication used for longer periods can be continued; patients are requested to keep medication stable during the course of the study)
* Having received ImRs (either as a stand-alone or embedded in a greater treatment such as cognitive behavior therapy (CBT) or schema therapy) within the last year
* No other evidence-based treatment of MDD is allowed during the study.
* Not able to plan enough time for weekly therapy sessions (45-60 minutes); weekly measurements (estimate of 5 minutes) and other measurements (estimate of 20 minutes); and the qualitative post-treatment interview (estimate of 60 minutes) during the study period.

Where it's running

• Academic Center for Trauma and Personality ACTP
  Amsterdam, Netherlands Recruiting

Study contacts

• Principal investigator: Arnoud Arntz, PhD — University of Amsterdam
• Study coordinator: Arnoud Arntz, PhD
• Email: a.r.arntz@uva.nl
• Phone: +31 20 525 6728

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized treatment for depression using therapy and medication

  This study is testing whether matching people with depression to the right treatment—either therapy or medication—can help them feel better when other treatments haven't worked.

  Recruiting Phase 4 Nova Scotia Health Authority · Halifax, Nova Scotia · NCT02752542

• Dupilumab for Major Depressive Disorder

  This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07908563

• Accelerated vs Standard iTBS for Major Depression

  This trial tests whether giving more accelerated iTBS sessions is better tolerated and more effective than the standard schedule for adults with major depressive disorder.

  Recruiting Military Hospital 175 · Ho Chi Minh City · NCT07768397

• Psilocybin with Structured Integrated Reframing Therapy for trauma-related MDD and PTSD

  This trial tests whether psilocybin therapy, alone or with Structured Integrated Reframing Therapy (SIRT), helps people with trauma-related major depressive disorder who are already on a stable antidepressant.

  Recruiting Phase 3 Khyber Medical University Peshawar · Islamabad, Capital and 2 other locations · NCT07703722

• Magnesium Bisglycinate Added to Your Depression Treatment

  This study tests whether adding magnesium bisglycinate to your current antidepressant can help reduce depressive symptoms and improve sleep and daily functioning for adults with major depressive disorder.

  Recruiting All India Institute of Medical Sciences, Bhubaneswar · Bhubaneswar, Odisha · NCT07633080

• Motif XCS System for treatment-resistant depression

  This study tests whether the Motif XCS System is safe and tolerable and might help people with treatment-resistant major depressive disorder.

  Recruiting at 4 sites Motif Neurotech, Inc. · Atlanta, Georgia and 3 other locations · NCT07594483

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.